Digital therapeutics have potential but commercial success unproven

Digital therapeutics have potential but commercial success unproven





Original Source


Somryst will, if approved, be another kind of first: Pear intends to market it alone. Reset and Reset-O are sold under a partnership with Novartis’s generics arm, Sandoz. Sandoz is a manufacturer of buprenorphine, an opioid addiction treatment, but Mr McCann says the two products are not sold bundled together. 

Pear has also partnered a couple of its pipeline products. Pear-004, in schizophrenia, and Pear-006, in multiple sclerosis, are in development with Novartis. Data from a large, sham-controlled trial of ’004 ought to emerge late this year or in early 2020; Mr McCann describes the study as “probably one of the most rigorous clinical trials that’s ever been run with a prescription digital therapeutic”. 

As with most schizophrenia drug trials, the trial’s efficacy endpoint will be change on the positive and negative syndrome scale. 

“That’s the point of what we do: to apply drug-like rigour so that clinicians know what works, patients get what works and payers can ultimately trust to pay for what works. Just like the drugs in this space.”

Development before profitability

Pear is so far the only company to have brought a digital therapeutic to market – but it is by no means the only company in this space. Akili Interactive has filed for FDA approval of AKL-T01, a computer game designed to treat ADHD, and another product, AKL-T02, is in late-stage development for cognitive dysfunction in children with autism spectrum disorder.

And Akili, like Pear, has received generous financial backing from venture investors. Akili raised $68m in a series C round last year from investors including Merck Ventures and Temasek, Singapore’s National Wealth Fund. Pear’s $64m series C, also involving Temasek with other backers including Novartis, was one of this year’s biggest (Medtech VC and the billion-dollar era, July 10, 2019).

Click Therapeutics, which makes apps for various neurological conditions and has partnered with Otsuka on the development and sale of its depression therapeutic CT-152, counts Sanofi and Hikma Pharmaceuticals among its investors. 

Perhaps drug companies see the development of digital products as a way of wringing some kind of financial reward out of CNS disorders given the difficulty of developing drugs in this area.

That said, no digital group has yet generated such a return. A private company, Pear has not opted to report sales figures and Mr McCann says the group is not interested in turning a profit at this stage. 

“Our mandate is to develop as many of these prescription digital therapeutics as we possibly can – our goal is really development of the space before it is profitability.”

Diverging paths

That said, developing digital therapeutics is not always straightforward. The San Diego-based group Dthera Sciences is chasing perhaps the most elusive target of all: a way of improving outcomes in Alzheimer’s disease. 

Edward Cox, chief executive of Dthera, explains that the group’s technology is a way of allowing large numbers of patients to undergo reminiscence therapy – a proven behavioural therapy for Alzheimer’s disease. 

The device shows agitated patients pictures or videos of themselves and their families from earlier in their lives as a way to calm them. 

The technology runs on a ruggedised tablet, which runs a second programme to scan the patients’ faces and track their emotional reactions. The software then compares those reactions to the content that is shown to maximise its effectiveness. 

Dthera is planning to run a pivotal trial of the tech. But the company has not had the same kind of financial success as some of the other groups in this space. Listed on the OTCQB, its shares have lost 97% of their value since the beginning of 2018, and a 20-for-one reverse split last September did not help the company reach its goal of uplisting to the Nasdaq.

In April Dthera said it was seeking a buyer, an investor or a development partner – it does have an exclusive agreement granting Japanese development and commercialisation rights for DTHR-ALZ to an unnamed company headquartered in Japan. 

Digital therapeutics is an area still in its infancy, and it will take time before it becomes clear whether other players will see the rapid regulatory success of Pear or follow in the less exalted footsteps of Dthera. 

But either way, it appears that it will be some time before digital therapeutics developers are able to post a profit. 

Selected digital therapeutics
Company Product Indication Status Partner
Pear Therapeutics Reset Substance use disorder Marketed Sandoz
Pear Therapeutics Reset-O Opioid use disorder Marketed Sandoz
Pear Therapeutics Pear-003/Somryst Insomnia/depression Filed with FDA  
Akili Interactive AKL-T01 ADHD Filed with FDA Shionogi
Pear Therapeutics Pear-004 Schizophrenia  Mid to late R&D Novartis
Akili Interactive AKL-T02 Autism spectrum disorder Mid to late R&D Shionogi
Click Therapeutics CT-152 Major depressive disorder Mid to late R&D Otsuka
Dthera Sciences  DTHR-ALZ Alzheimer’s disease Mid to late R&D Unnamed company
Click Therapeutics CT-101/Clickotine Smoking cessation Mid to late R&D  
Cognoa  Autism diagnostic Autism Mid to late R&D  
Cognoa  Autism therapeutic Autism Mid to late R&D  
Akili Interactive AKL-T03 Major depressive disorder Early R&D  
Click Therapeutics CT-111/Clickheart Acute coronary syndrome Early R&D  
Click Therapeutics CT-141/Clickadian Insomnia Early R&D  
Pear Therapeutics Pear-006 Multiple sclerosis Discovery Novartis
Source: company websites, press releases, interviews.






Subscribe To Sky-News

* indicates required



Follow us on Twitter